Phillip Pang - 24 Jan 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
24 Jan 2023
Net transactions value
-$836,269
Form type
4
Filing time
25 Jan 2023, 19:01:49 UTC
Previous filing
21 Jul 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $40,014 +25,406 +18% $1.58* 169,406 24 Jan 2023 Direct
transaction VIR Common Stock Award $23,774 +4,594 +2.7% $5.18 174,000 24 Jan 2023 Direct
transaction VIR Common Stock Sale $900,057 -30,000 -17% $30.00* 144,000 24 Jan 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -25,406 -65% $0.000000 13,576 24 Jan 2023 Common Stock 25,406 $1.58 Direct F3
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -4,594 -11% $0.000000 37,535 24 Jan 2023 Common Stock 4,594 $5.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.